Showing 1-10 of about 16 articles.
BiPar Sciences
PARIS and SOUTH SAN FRANCISCO, Calif., July 17, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its wholly owned subsidiary, BiPar Sciences, today announced the initiation of the...
BiPar Sciences
PARIS and BRISBANE, Calif., May 31, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2...
BiPar Sciences
BRISBANE, Kalifornien und PARIS, 20. Mai 2009 (GLOBE NEWSWIRE) -- Die
Ergebnisse der Phase II einer klinischen Studie von BiPar Science - einem
Tochterunternehmen im Besitz von sanofi-aventis - über...
BiPar Sciences
BSI-201 Phase II Data in Metastatic Triple-Negative Breast Cancer Featured At
ASCO Press Briefing; Study Results Will be Released On Sunday, May 31, 2009, At
8:30 a.m. EDT (Orlando, FL)...
BiPar Sciences
Les données de phase II du BSI-201 dans le cancer du sein métastatique triple
négatif seront présentées lors d'une conférence de presse officielle de l'ASCO
et intégrées au programme de formation «...
BiPar Sciences
BRISBANE, Calif. and PARIS, May 18, 2009 (GLOBE NEWSWIRE) -- Results from a Phase II clinical trial of BiPar Sciences' -- a wholly-owned sanofi-aventis subsidiary -- lead PARP inhibitor, BSI-201, will...
BiPar Sciences
BRISBANE, Calif. and PARIS, April 15, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) announced today that it has signed a binding agreement for the acquisition of BiPar Sciences,...
BiPar Sciences
BRISBANE, Calif., Feb. 3, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that President...
BiPar Sciences
BRISBANE, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today it has raised...
BiPar Sciences
BRISBANE, Calif., Jan. 7, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that Hoyoung...
Showing 1-10 of about 16 articles.
